The journal of vascular access · 2026
From assumption to assurance: Real-time flow monitoring in neonatal infusions.
Редакционная статьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
van Rens Matheus F P T, Barone Giovanni, van der Lee Robin, Piersigilli Fiammetta
Аннотация
BACKGROUND: In neonatal intensive care, infusion pumps display programmed flow rather than directly confirming drug delivery at the patient-end. At the low infusion rates used in neonatal practice, studies have shown that factors such as compliance, hydrostatic pressure, start-up delay, and partial occlusion can influence actual drug delivery. Although these phenomena are well described, continuous bedside confirmation of patient-end flow isn't available in routine practice.
PURPOSE: This editorial discusses the clinical implications of this hidden gap and explores the potential role of real-time flow monitoring.
MAIN MESSAGE: We review the mechanisms contributing to flow variability, discuss why conventional pumps cannot verify patient-end drug delivery, and propose a phased pathway for evaluating emerging flow-monitoring technologies. We emphasize that current evidence is based on engineering and early translational studies and that clinical benefit remains to be demonstrated.
CONCLUSION: Improving visibility of patient-end drug delivery may represent future directions for neonatal infusion safety and warrants clinical evaluation.
PURPOSE: This editorial discusses the clinical implications of this hidden gap and explores the potential role of real-time flow monitoring.
MAIN MESSAGE: We review the mechanisms contributing to flow variability, discuss why conventional pumps cannot verify patient-end drug delivery, and propose a phased pathway for evaluating emerging flow-monitoring technologies. We emphasize that current evidence is based on engineering and early translational studies and that clinical benefit remains to be demonstrated.
CONCLUSION: Improving visibility of patient-end drug delivery may represent future directions for neonatal infusion safety and warrants clinical evaluation.